CORDIS
EU research results

CORDIS

English EN

Stem-cell based therapy for kidney repair

Objective

Chronic kidney disease (CKD) affects 8% of the European population and ultimately results in renal failure due to progressive fibrosis. CDK carries a high mortality risk and the number of affected people rises, increasing the demand on renal replacement therapies while the number of available donor organs stays stable.

The STELLAR consortium proposes to develop an alternative to renal replacement therapy, based on the repair capacity of newly discovered kidney mesenchymal stromal cells (kMSCs). By injecting kMSC into affected kidneys, we expect to stop kidney fibrosis and induce tissue repair, ultimately leading to the restoration of normal kidney function.

The STELLAR consortium will
• develop protocols for up scalable, high quality isolation of kMSCs and precisely characterize kMSC function in comparison to other MSCs.
• test kMSCs in several murine renal disease models, to study their effects on fibrosis and tissue repair.
• discover mechanisms of kidney repair.
• invest in developing the technology necessary for up scaled isolation and quality control.

The STELLAR consortium combines Australian experts on kMSC isolation and characterisation with European experts on renal failure and compounds the state-of-the-art knowledge, facilities and experience needed to develop and validate this novel form of renal therapy. The inclusion of experienced SMEs, with great technical and scientific know-how about assay and protocol development, further strengthens the consortium and will ensure not only the inclusion of new technology, but also a quick translation from bench to clinical application.

In conclusion, the STELLAR consortium is capable of developing and pre clinical validation of this new cellular therapy for CDK, based on a new understanding of stromal cells and fibroblast function, while also providing the technology required for rapid, large scale application of the therapy after clinical validation.

Coordinator

ACADEMISCH ZIEKENHUIS LEIDEN

Address

Albinusdreef 2
2333 Za Leiden

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 327 941

Administrative Contact

A.J. Rabelink (Prof.)

Participants (15)

Sort alphabetically

Sort by EU Contribution

Expand all

THE UNIVERSITY OF QUEENSLAND

Australia

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

Italy

EU Contribution

€ 850 960

UNIVERSITA DEGLI STUDI DI FIRENZE

Italy

EU Contribution

€ 402 500

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 74 159,78

THE ANTIBODY LAB GMBH

Austria

EU Contribution

€ 616 814,50

KUROS BIOSCIENCES BV

Netherlands

EU Contribution

€ 1 012 157,60

MILTENYI BIOTEC GMBH

Germany

EU Contribution

€ 413 000

UNIVERSITEIT TWENTE

Netherlands

EU Contribution

€ 334 259,35

NIERSTICHTING NEDERLAND

Netherlands

THE AUSTRALIAN KIDNEY FOUNDATION - KIDNEY HEALTH AUSTRALIA

Australia

AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII

Italy

EU Contribution

€ 104 400

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 437 140,62

MURDOCH CHILDRENS RESEARCH INSTITUTE

Australia

UNIVERSITEIT MAASTRICHT

Netherlands

EU Contribution

€ 424 717,15

SCINUS CELL EXPANSION BV

Netherlands

Project information

Grant agreement ID: 305436

Status

Closed project

  • Start date

    1 November 2012

  • End date

    31 October 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 9 642 381,40

  • EU contribution

    € 5 998 050

Coordinated by:

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands